We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy.
- Authors
Lin, Ying-Chun; Chen, Yu-Chia; Chen, Rui-Yun; Huang, Yi-Xuan; Tu, Siang-Jyun; Liang, Ji-An; Hung, Yao-Ching; Yeh, Lian-Shung; Chang, Wei-Chun; Lin, Wu-Chou; Chang, Yin-Yi; Chen, Shang-Wen; Chang, Jan-Gowth
- Abstract
This study investigated the prognostic effects of genomic biomarkers for predicting chemoradiotherapy (CRT)-based treatment outcomes in patients with adenocarcinoma (AC) of the uterine cervix. In all, 21 patients receiving definitive CRT were included. In accordance with the International Federation of Gynecology and Obstetrics (FIGO) staging system, 5, 8, and 8 patients were classified as having stage IB3, II, and III disease, respectively. Pretreatment biomarkers were analyzed using tissue microarrays from biopsy specimens. Genomic alterations were examined by next-generation sequencing (NGS). The outcome endpoints were disease-free survival (DFS), distant metastasis-free survival (DMFS), and local relapse-free survival (LRFS). A Cox regression model was used to examine the prognostic effects of the biomarkers and clinical parameters. The presence of myeloid cell leukemia-1 (MCL1) gene amplification and a lower immunohistochemical (IHC) marker of tumor necrotic factor alpha (TNF-α) H-score were two prognostic factors for inferior DFS. The four-year DFS was 28% and 68% for patients with or without MCL1 copy number gain, respectively (p = 0.028). In addition, MCL1 amplification predicted poor DMFS. A lower tumor mutation number (TMN) calculated from nonsynonymous mutations was associated with lower LRFS. For patients with adenocarcinoma of the uterine cervix receiving definitive CRT, prognostic information can be supplemented by MCL1 amplification, the TMN, and the TNF-α H score.
- Subjects
CERVIX uteri; CHEMORADIOTHERAPY; ACROMIOCLAVICULAR joint; TUMOR markers; BIOMARKERS; ADENOCARCINOMA; PHARMACOGENOMICS; GENE amplification
- Publication
International Journal of Molecular Sciences, 2020, Vol 21, Issue 11, p4117
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms21114117